R Daniel Beauchamp
Overview
Explore the profile of R Daniel Beauchamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
2460
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rellinger E, Padmanabhan C, Qiao J, Craig B, An H, Zhu J, et al.
Oncotarget
. 2017 Dec;
8(53):91040-91051.
PMID: 29207623
Neuroblastomas are the most common extracranial solid tumors in children and arise from the embryonic neural crest. -amplification is a feature of ∼30% of neuroblastoma tumors and portends a poor...
12.
Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez R, Berlin J, et al.
J Surg Oncol
. 2017 Sep;
117(2):284-289.
PMID: 28940307
Background And Objectives: The World Health Organization (WHO) 2010 has classified GI neuroendocrine neoplasms into neuroendocrine tumor (NET) and high-grade neuroendocrine carcinoma (NEC). The genetic underpinnings of NEC are poorly...
13.
Rellinger E, Padmanabhan C, Qiao J, Appert A, Waterson A, Lindsley C, et al.
Biochem Biophys Res Commun
. 2017 Jul;
491(2):463-468.
PMID: 28716733
Ewing sarcomas are rare mesenchymal-derived bone and soft tissue tumors in children. Afflicted children with distant metastases have poor survival despite aggressive therapeutics. Epithelial-to-mesenchymal transition in epithelial carcinomas is associated...
14.
Ma Y, Wang L, Neitzel L, Loganathan S, Tang N, Qin L, et al.
Clin Cancer Res
. 2016 Sep;
23(8):2027-2037.
PMID: 27678457
The bromodomain and extra-terminal domain (BET) family proteins are epigenetic readers for acetylated histone marks. Emerging BET bromodomain inhibitors have exhibited antineoplastic activities in a wide range of human cancers...
15.
Zhu J, Deane N, Lewis K, Padmanabhan C, Washington M, Ciombor K, et al.
Sci Rep
. 2016 Sep;
6:33273.
PMID: 27623752
Defining molecular features that can predict the recurrence of colorectal cancer (CRC) for stage II-III patients remains challenging in cancer research. Most available clinical samples are Formalin-Fixed, Paraffin-Embedded (FFPE). NanoString...
16.
Gonzalez R, Huh W, Cates J, Washington K, Beauchamp R, Coffey R, et al.
Histopathology
. 2016 Aug;
70(2):223-231.
PMID: 27560620
Aims: Colorectal carcinoma (CRC) with micropapillary (MP) features has only been described recently and is still being characterized. Methods And Results: We reviewed the clinicopathological and molecular features of 42...
17.
Chen X, Deane N, Lewis K, Li J, Zhu J, Washington M, et al.
PLoS One
. 2016 May;
11(5):e0153784.
PMID: 27176004
The prognosis of colorectal cancer (CRC) stage II and III patients remains a challenge due to the difficulties of finding robust biomarkers suitable for testing clinical samples. The majority of...
18.
Brogan J, Stoops S, Brady S, An H, Weaver C, Daniels J, et al.
Bioorg Med Chem Lett
. 2015 Aug;
25(19):4260-4.
PMID: 26299347
E-cadherin is a ubiquitous trans-membrane protein that has important functions in cellular contacts and has been shown to play a role in the epithelial mesenchymal transition. We have previously reported...
19.
French C, Ye F, Revetta F, Zhang B, Coffey R, Washington M, et al.
F1000Res
. 2015 Jun;
4:99.
PMID: 26097693
A key question in cancer systems biology is how to use molecular data to predict the biological behavior of tumors from individual patients. While genomics data have been heavily used,...
20.
St Julien J, Lang R, Brown T, Aldrich M, Deppen S, Wu H, et al.
J Racial Ethn Health Disparities
. 2014 Nov;
1(4):238-246.
PMID: 25396113
Background: Underrepresentation of minorities within academic surgery is an ever present problem with a profound impact on healthcare. The factors influencing surgery residents to pursue an academic career have yet...